Correlation Between Egetis Therapeutics and Lipigon Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Egetis Therapeutics and Lipigon Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Egetis Therapeutics and Lipigon Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Egetis Therapeutics AB and Lipigon Pharmaceuticals AB, you can compare the effects of market volatilities on Egetis Therapeutics and Lipigon Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Egetis Therapeutics with a short position of Lipigon Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Egetis Therapeutics and Lipigon Pharmaceuticals.

Diversification Opportunities for Egetis Therapeutics and Lipigon Pharmaceuticals

0.15

Correlation Coefficient

Egetis Therapeutics  Lipigon Pharmaceuticals

Average diversification

The 3 months correlation between Egetis and Lipigon is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Egetis Therapeutics AB and Lipigon Pharmaceuticals AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Lipigon Pharmaceuticals and Egetis Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Egetis Therapeutics AB are associated (or correlated) with Lipigon Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Lipigon Pharmaceuticals has no effect on the direction of Egetis Therapeutics i.e., Egetis Therapeutics and Lipigon Pharmaceuticals go up and down completely randomly.

Pair Corralation between Egetis Therapeutics and Lipigon Pharmaceuticals

Assuming the 90 days trading horizon Egetis Therapeutics AB is expected to generate 0.43 times more return on investment than Lipigon Pharmaceuticals. However, Egetis Therapeutics AB is 2.3 times less risky than Lipigon Pharmaceuticals. It trades about -0.07 of its potential returns per unit of risk. Lipigon Pharmaceuticals AB is currently generating about -0.06 per unit of risk. If you would invest  566.00  in Egetis Therapeutics AB on December 4, 2024 and sell it today you would lose (91.00) from holding Egetis Therapeutics AB or give up 16.08% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Egetis Therapeutics AB  vs.  Lipigon Pharmaceuticals AB

Egetis Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Egetis Therapeutics AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Lipigon Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Lipigon Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Egetis Therapeutics and Lipigon Pharmaceuticals

The main advantage of trading using opposite Egetis Therapeutics and Lipigon Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Egetis Therapeutics position performs unexpectedly, Lipigon Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipigon Pharmaceuticals will offset losses from the drop in Lipigon Pharmaceuticals' long position.

The idea behind Egetis Therapeutics AB and Lipigon Pharmaceuticals AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.